Hussman Strategic Advisors, Inc. Biocryst Pharmaceuticals Inc Transaction History
Hussman Strategic Advisors, Inc.
- $428 Million
- Q3 2025
A detailed history of Hussman Strategic Advisors, Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Hussman Strategic Advisors, Inc. holds 210,000 shares of BCRX stock, worth $1.49 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
210,000
Previous 210,000
-0.0%
Holding current value
$1.49 Million
Previous $1.88 Million
15.31%
% of portfolio
0.37%
Previous 0.46%
Shares
2 transactions
Others Institutions Holding BCRX
# of Institutions
314Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$60.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$60 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$40.5 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...